ATE517855T1 - Antikörper gegen chemotaktische monozytenproteine - Google Patents

Antikörper gegen chemotaktische monozytenproteine

Info

Publication number: ATE517855T1
Authority: AT; Austria
Prior art keywords: antibodies; monocyte proteins; chemotactic; chemotactic monocyte; proteins
Prior art date: 2001-11-30

Application number

AT02792310T

Other languages

English (en)

Inventor

Fougerolles Antonin De

Victor Kotelianski

Ellen Garber

Carl Reid

Original Assignee

Biogen Idec Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-30

Filing date

2002-11-27

Publication date

2011-08-15

2002-11-27 Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc

2011-08-15 Application granted granted Critical

2011-08-15 Publication of ATE517855T1 publication Critical patent/ATE517855T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT02792310T 2001-11-30 2002-11-27 Antikörper gegen chemotaktische monozytenproteine ATE517855T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US34339101P	2001-11-30	2001-11-30
US38327702P	2002-05-24	2002-05-24
US40046902P	2002-08-01	2002-08-01
PCT/US2002/038229 WO2003048083A2 (en)	2001-11-30	2002-11-27	Antibodies against monocyte chemotactic proteins

Publications (1)

Publication Number	Publication Date
ATE517855T1 true ATE517855T1 (de)	2011-08-15

Family

ID=27407563

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02792310T ATE517855T1 (de)	2001-11-30	2002-11-27	Antikörper gegen chemotaktische monozytenproteine

Country Status (8)

Country	Link
US (6)	US7405277B2 (de)
EP (3)	EP2298717B1 (de)
AR (1)	AR037456A1 (de)
AT (1)	ATE517855T1 (de)
AU (1)	AU2002357770B2 (de)
CA (1)	CA2468733C (de)
DK (1)	DK1461300T3 (de)
WO (1)	WO2003048083A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2298717B1 (de) *	2001-11-30	2015-10-28	Biogen MA Inc.	Antikörper gegen chemotaktische Proteine
EP1540013B1 (de) *	2002-08-19	2015-07-08	The President and Fellows of Harvard College	Entwicklung einer neuen molekularen funktion
GB0228832D0 (en)	2002-12-10	2003-01-15	Novartis Ag	Organic compound
US7964194B2 (en) *	2002-11-15	2011-06-21	Morehouse School Of Medicine	Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation
CA2507080C (en) *	2002-11-27	2015-01-06	Biogen Idec Ma Inc.	Humanized antibodies against monocyte chemotactic proteins
GB0321997D0 (en) *	2003-09-19	2003-10-22	Novartis Ag	Organic compound
CA2544924A1 (en) *	2003-11-05	2005-05-19	Centocor, Inc.	Methods and compositions for treating mcp-1 related pathologies
EP1730277B1 (de) *	2004-03-22	2009-10-28	Nuevolution A/S	Ligationscodierung unter verwendung von oligonukleotidbausteinen
AU2011265315B2 (en) *	2004-05-12	2014-08-28	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods related to the treatment of neurodegenerative and inflammatory conditions
CA2566445C (en)	2004-05-12	2016-02-02	The Government Of The United States As Represented By The Secretary, Department Of Health And Human Services	Methods related to the treatment of neurodegenerative and inflammatory conditions
US7371825B2 (en) *	2004-06-30	2008-05-13	Centocor, Inc.	Anti-MCP-1 antibodies, compositions, methods and uses
US8114964B2 (en)	2005-05-19	2012-02-14	Centocor, Inc.	Anti-MCP-1 antibodies, compositions, methods and uses
PA8675801A1 (es) *	2005-05-19	2006-12-07	Centocor Inc	Anticuerpos anti-mcp-1, composiciones, metodos y usos
US20070099239A1 (en) *	2005-06-24	2007-05-03	Raymond Tabibiazar	Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
EP2039766A4 (de) *	2006-06-05	2010-06-16	Univ Hiroshima	Immunkompetente zelle mit anti-cd38-antikörper auf ihrer oberfläche
US20080076120A1 (en) *	2006-09-14	2008-03-27	Millennium Pharmaceuticals, Inc.	Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
HRP20140512T1 (hr) *	2006-10-02	2014-07-04	Regeneron Pharmaceuticals, Inc.	Humana antitijela s visokim afinitetom za humani il-4 receptor
US7608693B2 (en)	2006-10-02	2009-10-27	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human IL-4 receptor
JP5403752B2 (ja) *	2007-06-22	2014-01-29	北海道公立大学法人札幌医科大学	移植片対宿主疾患の検査および治療方法
KR101772706B1 (ko)	2008-08-18	2017-08-29	화이자 인크.	Ｃｃｒ２에 대한 항체
CA2779683A1 (en) *	2009-11-10	2011-05-19	Amgen Inc.	Anti-c-mpl antibodies
WO2011129382A1 (en) *	2010-04-16	2011-10-20	Abbott Japan Co. Ltd.	Methods and reagents for diagnosing rheumatoid arthritis
GB201205739D0 (en) *	2012-03-30	2012-05-16	Ucl Business Plc	Treatment of acute inflammation in the respiratory tract
HK1208819A1 (en) *	2012-05-22	2016-03-18	夏尔人类遗传性治疗公司	Anti-ccl2 antibodies for treatment of scleroderma
CA2882416A1 (en)	2012-08-21	2014-02-27	Sanofi	Methods for treating or preventing asthma by administering an il-4r antagonist
CN105358175B (zh) *	2013-05-23	2020-10-16	夏尔人类遗传性治疗公司	用于治疗硬皮病的抗ccl2和抗loxl2组合疗法
TWI697334B (zh)	2013-06-04	2020-07-01	美商再生元醫藥公司	藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI682781B (zh)	2013-07-11	2020-01-21	美商再生元醫藥公司	藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
US10370449B2 (en)	2014-02-28	2019-08-06	Regeneron Pharmaceuticals, Inc.	Methods for treating skin infection by administering an IL-4R antagonist
KR20170081262A (ko)	2014-11-14	2017-07-11	사노피 바이오테크놀로지	Ｉｌ-4ｒ 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법
EP3613435A1 (de)	2015-01-28	2020-02-26	Universite De Bordeaux	Inhibitoren des chemokinrezeptor cxcr4 zur behandlung und/oder vorbeugung chronisch obstruktiver lungenerkrankung
WO2018045130A1 (en)	2016-09-01	2018-03-08	Regeneron Pharmaceuticals, Inc.	Methods for preventing or treating allergy by administering an il-4r antagonist
WO2018057776A1 (en)	2016-09-22	2018-03-29	Regeneron Pharmaceuticals, Inc.	Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
WO2019028367A1 (en)	2017-08-04	2019-02-07	Regeneron Pharmaceuticals, Inc.	METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
CN111526920A (zh)	2017-10-30	2020-08-11	赛诺菲生物技术公司	通过施用il-4r拮抗剂来治疗或预防哮喘的方法
CN120227453A (zh)	2018-05-13	2025-07-01	瑞泽恩制药公司	用于通过施用il-4r抑制剂治疗特应性皮炎的方法
US20210382028A1 (en) *	2018-10-11	2021-12-09	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Means and methods for detecting soy allergens
PH12021552123A1 (en)	2019-03-21	2022-08-22	Regeneron Pharma	Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
TWI868126B (zh)	2019-04-17	2025-01-01	國立大學法人廣島大學	以組合投予il-6 抑制劑與ccr2 抑制劑為特徵之泌尿器官癌的治療劑
BR112022000581A2 (pt)	2019-08-05	2022-03-03	Regeneron Pharma	Métodos para tratamento de alergia e intensificação de imunoterapia específica dos alergénos através da administração de um antagonista de il-4r
EP4010373A1 (de)	2019-08-05	2022-06-15	Regeneron Pharmaceuticals, Inc.	Verfahren zur behandlung atopischer dermatitis durch verabreichung eines il-4r-antagonisten

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
DE3572982D1 (en)	1984-03-06	1989-10-19	Takeda Chemical Industries Ltd	Chemically modified lymphokine and production thereof
JPS6147500A (ja)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
JPS61134325A (ja)	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
EP0279582A3 (de)	1987-02-17	1989-10-18	Pharming B.V.	DNA-Sequenzen die Proteine zwecks effizienter Abscheidung zur Milchdrüse leiten
ATE135370T1 (de)	1988-12-22	1996-03-15	Kirin Amgen Inc	Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5633076A (en)	1989-12-01	1997-05-27	Pharming Bv	Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
AU675916B2 (en)	1991-06-14	1997-02-27	Genentech Inc.	Method for making humanized antibodies
JPH05244982A (ja)	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
US5714350A (en)	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5510264A (en)	1993-09-28	1996-04-23	Insight Biotech Inc.	Antibodies which bind meningitis related homologous antigenic sequences
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
GB9424449D0 (en)	1994-12-02	1995-01-18	Wellcome Found	Antibodies
JPH0967399A (ja)	1995-08-30	1997-03-11	Mitsui Toatsu Chem Inc	抗ｍｃｐ−１ヒトモノクローナル抗体
SE9600820D0 (sv) *	1996-03-01	1996-03-01	Pharmacia Ab	Antibodies and their use
US6312689B1 (en)	1998-07-23	2001-11-06	Millennium Pharmaceuticals, Inc.	Anti-CCR2 antibodies and methods of use therefor
WO2001057226A1 (en)	2000-02-03	2001-08-09	Millennium Pharmaceuticals, Inc.	Humanized anti-ccr2 antibodies and methods of use therefor
CA2409298A1 (en)	2000-05-19	2001-11-29	The Government Of The United States Of America	Methods for reducing tumor growth and metastasis by inhibiting mcp-1 activity
US7309693B2 (en)	2000-05-26	2007-12-18	Kensuke Egashira	Preventives and remedies for pulmonary hypertension
GB0016138D0 (en)	2000-06-30	2000-08-23	Novartis Ag	Organic compounds
EP2298717B1 (de)	2001-11-30	2015-10-28	Biogen MA Inc.	Antikörper gegen chemotaktische Proteine
CA2507080C (en)	2002-11-27	2015-01-06	Biogen Idec Ma Inc.	Humanized antibodies against monocyte chemotactic proteins
IT1395574B1 (it)	2009-09-14	2012-10-16	Guala Dispensing Spa	Dispositivo di erogazione

2002
- 2002-11-27 EP EP10180666.9A patent/EP2298717B1/de not_active Expired - Lifetime
- 2002-11-27 AR ARP020104579A patent/AR037456A1/es not_active Application Discontinuation
- 2002-11-27 EP EP15185855.2A patent/EP2990394A1/de not_active Withdrawn
- 2002-11-27 DK DK02792310.1T patent/DK1461300T3/da active
- 2002-11-27 AU AU2002357770A patent/AU2002357770B2/en not_active Expired
- 2002-11-27 CA CA2468733A patent/CA2468733C/en not_active Expired - Lifetime
- 2002-11-27 AT AT02792310T patent/ATE517855T1/de not_active IP Right Cessation
- 2002-11-27 WO PCT/US2002/038229 patent/WO2003048083A2/en not_active Application Discontinuation
- 2002-11-27 EP EP02792310A patent/EP1461300B1/de not_active Expired - Lifetime
2004
- 2004-05-27 US US10/855,013 patent/US7405277B2/en not_active Expired - Lifetime
2008
- 2008-07-11 US US12/171,791 patent/US7632501B2/en not_active Expired - Lifetime
2009
- 2009-11-04 US US12/612,087 patent/US7972597B2/en not_active Expired - Lifetime
2011
- 2011-06-09 US US13/156,959 patent/US8431125B2/en not_active Expired - Lifetime
2013
- 2013-04-16 US US13/863,574 patent/US9096665B2/en not_active Expired - Lifetime
2015
- 2015-06-22 US US14/746,555 patent/US20160185846A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20100166757A1 (en)	2010-07-01
EP2990394A1 (de)	2016-03-02
US20050025768A1 (en)	2005-02-03
HK1155720A1 (en)	2012-05-25
WO2003048083A2 (en)	2003-06-12
US7632501B2 (en)	2009-12-15
US20160185846A1 (en)	2016-06-30
WO2003048083A3 (en)	2004-01-15
CA2468733C (en)	2013-06-11
AU2002357770B2 (en)	2008-07-31
EP1461300B1 (de)	2011-07-27
EP2298717B1 (de)	2015-10-28
US20140178382A1 (en)	2014-06-26
DK1461300T3 (da)	2011-10-24
AU2002357770A1 (en)	2003-06-17
EP1461300A4 (de)	2005-12-28
AR037456A1 (es)	2004-11-10
US7405277B2 (en)	2008-07-29
US20090017028A1 (en)	2009-01-15
CA2468733A1 (en)	2003-06-12
US7972597B2 (en)	2011-07-05
US9096665B2 (en)	2015-08-04
EP2298717A1 (de)	2011-03-23
US8431125B2 (en)	2013-04-30
EP1461300A2 (de)	2004-09-29
US20120039873A1 (en)	2012-02-16

Publication	Publication Date	Title
ATE517855T1 (de)	2011-08-15	Antikörper gegen chemotaktische monozytenproteine
DE60236735D1 (de)	2010-07-29	Antikörper gegen vla-1
DE60134148D1 (de)	2008-07-03	Antikörper gegen il-1 beta
EP1448787A4 (de)	2006-06-07	Menschliche monoklonale antikörper gegen dendritische zellen
EP1499352A4 (de)	2006-10-11	Rekombinante anti-interleukin-9-antikörper
NO20044347L (no)	2004-12-13	Anti-alfavbeta6-antistoff
EP1396500A4 (de)	2005-02-02	Anti-trail-r-antikörper
DK1599504T3 (da)	2015-03-09	Modificeret antistof
DE60222658D1 (de)	2007-11-08	Monoklonaler anti-cd-40-antikörper
DE602004022855D1 (de)	2009-10-08	Interleukin-10-antikörper
CY2012003I1 (el)	2016-12-14	Αντισωματα που συνδεονται ανοσοειδικως προς blys
NO20023677D0 (no)	2002-08-02	Sementeringsmanifold-enhet
NO20032612L (no)	2003-08-05	CXCR3-antagonister
ATE426616T1 (de)	2009-04-15	Antikírper gegen menschliches mcp-1
DE60210864D1 (de)	2006-06-01	Modifiziertes fluoreszentes Protein
DK1752470T3 (da)	2009-12-14	GAG-bindende proteiner
DE60127237D1 (de)	2007-04-26	Therapeutischer monoklonaler rekombinanter anti-ige antikörper gegen hunde-allergie
DE60129572D1 (de)	2007-09-06	Verwendung von antikörpern gegen spezifische mhc-peptidkomplexe
EE200300569A (et)	2004-04-15	CD44v6-spetsiifilised antikehad
ATE513564T1 (de)	2011-07-15	Immunogener rekombinanter antikörper
EP1464701A4 (de)	2005-05-11	Fluoreszenzproteine
DE60134224D1 (de)	2008-07-10	Ansaugkrümmer
DE60201466D1 (de)	2004-11-11	Einlasskrümmer
ATE278712T1 (de)	2004-10-15	Antikörper gegen plazentaprotein 13
FI20011055L (fi)	2002-11-19	Heveiiniä sitovat monoklonaaliset vasta-aineet

Legal Events

Date	Code	Title	Description
2012-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties